ImmuPharma (LON:IMM) Shares Up 86.7% – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s share price was up 86.7% on Thursday . The stock traded as high as GBX 2.49 ($0.03) and last traded at GBX 2.24 ($0.03). Approximately 12,117,709 shares were traded during mid-day trading, an increase of 314% from the average daily volume of 2,929,006 shares. The stock had previously closed at GBX 1.20 ($0.01).

ImmuPharma Stock Up 4.9 %

The company has a market cap of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The company has a fifty day simple moving average of GBX 1.40 and a two-hundred day simple moving average of GBX 1.65.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.

Recommended Stories

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.